A strong quarter for both our pharma sales and our sales of Covid-19 tests
July - September
- Consolidated sales during the second quarter, July to September amounted to
SEK 52.5 (24.2) million. Adjusted for non-recurring sales the revenue amounted to 34.5 (24.2) MSEK, an increase of 42.6%. - Gross profit amounted to
SEK 16.3 (10.4) million for the quarter, an increase of 56.4%. - EBIT for the quarter was
SEK 5.9 (3.4) million. - Earnings per share were SEK 0:18 (0:11) for the quarter.
- Cash flow from operating activities amounted to
SEK 4.3 (-40.0) million for the quarter. - Cash and cash equivalents were
SEK 8.0 (19.7) million at the end of the quarter.
April - September
- Consolidated sales during the period April-September amounted to
SEK 89.1 (123.7) million. Adjusted for non-recurring sales the revenue amounted to 66.1 (46.6) MSEK, an increase of 41.8%. - Gross profit for the same period amounted to
SEK 34.2 (32.8) million, a decrease of 4%. - EBIT for April-September amounted to
SEK 9.0 (15.0) million. - Earnings per share were SEK 0:27 (0:50) for the period.
- Cash flow from operating activities amounted to
SEK -4.2 (16.2) million during April-September. - Cash and cash equivalents were
SEK 8.0 (19.7) million at the end of September.
CEO's comments
The second quarter of 2021/22 was a strong quarter for the company in which our Covid-19 tests and our pharmaceuticals performed well. Total sales amounted to
One of our bestselling products, EQL Potassium Chloride, have previously been sold via a license agreement in
With regard to new approvals, the drug Ondansetron EQL Pharma has received a market authorization from the
The product development of our pharmaceuticals is also in an intensive phase with no less than 11 products that have now been submitted to the pharmaceutical authorities for review and 7 products that are now approved for sale and will be launched in the coming quarters. In the next financial year, more than 10 products are targeted to be launched, which would be a new record for
In the last quarter, our "nasal tops" Covid-19 self-tests sold successfully at main pharmacy chains and grocery retailers in
In addition to summing up a strong second quarter, I would also like to mention that we continue to work hard on the expansion of our products into the European market and have begun several license discussions for the products and markets where we do not plan to sell ourselves.
For further information, please contact:
Christer Fåhraeus
CEO,
Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
https://news.cision.com/eql-pharma/r/interim-report-april---september-2021,c3450922
https://mb.cision.com/Main/11664/3450922/1494117.pdf
(c) 2021 Cision. All rights reserved., source